A new high -tech implant that safely triggers powerful immune responses against difficult to treat cancer has shown a “promise” in the fight against some of the deadliest forms of cancer, including metastatic melanoma, pancreatic and colorectal tumors.
The implantable cancer control system, nicknamed “Cytokine Factory”, was developed by a team of Radio-Lacing Researchers at Rice in Houston, Texas.
Placed near the tumor microenvironnement, the device can distribute cells designed to release the Interleukin-12 protein (IL-12) which successfully induces the recruitment of specialized immune cells called the ex exhausted T cells (TPEX cells).
The recruitment of VISX cells results in a large sustainable population of T cells targeting the tumor, according to A published study In The Journal of Immunotherapy of Cancer.
“We have designed the Cytokines IL-12 factory to improve immunotherapy approaches while minimizing toxicity, a critical need in the treatment of particularly aggressive cancers,” said the main study teacher Omid Veeh, director of the faculty of the Rice Biotech Launch Pad.
Related:: Scientists discover a simple supplement which causes self-destruction of prostate cancer cells
The IL -12 cytokine factories, combined with control point inhibitors, have managed to eliminate local and distal tumors from preclinical models of metastatic melanoma and colorectal and pancreatic cancer – and have also demonstrated security in mice and non -human primates, according to the results.
THE The team said The study will serve as the basis for a new application of medication inquiry with the American FDA early next year. They also plan to launch an emerging biotechnology company based on the revolutionary technology of the Cytokines IL-12 factory.
“IL-12 is particularly impactful compared to other cytokines, because our research shows that other cytokines mainly recruit homogeneous T lymphocytes and show reduced efficiency over time, while IL-12 generates a more robust anti-tumor response by recruiting a more lasting and wider repertoire of tumor T cells.
Dr. Nathan Reticker-Flynn, of the University of Stanford, explained that the use of immunotherapy to target solid tumors has become common, but it is often a “difficult approach” because of the challenge of toxicity.
“Our study shows not only the effectiveness of this technology in preclinical models, but also its safety profile, which is an essential aspect while we are heading for clinical trials.”
Large news of cancer:: Hope for patients with aggressive breast cancer: vaccine trials cause a survival rate of 88% after 3 years
He calls this an “important step in the quest to provide more effective treatments” for patients fighting against metastatic cancers.
“We hope that this technology will have a significant impact on the life of cancer patients by improving the effectiveness of immunotherapy approaches to the clinic,” said Professor VEEH.
Divide good news by sharing this on social networks …